Trefoil Therapeutics Enters into Collaborative Research and Development Agreement with NIH to Accelerate Development of Fuchs Dystrophy TherapyTrefoil Therapeutics announced it will collaborate with NCATS to complete the investigational new drug enabling activities for their lead compound, TTHX1114, toward a treatment for Fuchs endothelial corneal dystrophy (FECD). Approximately 70,000 people suffer from FECD, which can lead to severe vision loss and for which there currently is no FDA-approved pharmaceutical therapy. Trefoil is developing TTHX1114 as potentially the first medical therapy for treatment of FECD, which is the most common driver of corneal transplantation.
